Zealand Pharma steadfastly upholds amylin-based obesity drug strategy
Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...
Hims & Hers Health: The Ultimate Pick For The Next Decade
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...
Daily13h
Dr Reddy's Laboratories Gets CDSCO Panel Nod To Study Semaglutide in Type 2 Diabetes Mellitus
Semaglutide is a GLP-1 agonist that works by reducing appetite, delaying gastric emptying, increasing insulin release, and lowering the amount of glucagon released. Semaglutide is a glucagon-like ...